Literature DB >> 1464372

Carnitine function and requirements during the life cycle.

C J Rebouche1.   

Abstract

L-Carnitine has been described as a "conditionally essential" nutrient for humans. Segments of the human population suggested as having a requirement for carnitine include infants (premature and full-term), patients on long-term parenteral nutrition, and perhaps children. The evidence to support these claims includes 1) low circulating carnitine concentrations; 2) abnormal (or at least different) circulating metabolite concentrations (free fatty acids, triglycerides, ketone bodies), and 3) very limited and inconsistent growth data. A number of subjective observations and anecdotal case reports have been offered in support of a requirement for carnitine. Exogenous carnitine is required to maintain "normal" (in the epidemiologic sense) plasma or serum carnitine concentrations in humans of all ages. But "functional carnitine deficiency," defined by abnormal clinical presentation correctable by carnitine administration, has not been demonstrated in an otherwise normal (nonpathologic) population. On the other hand, nutritional or pharmacological intervention with carnitine or its esters may be beneficial for very premature infants, infants and children with various clinical conditions associated with low circulating carnitine concentrations, and in some chronic diseases associated with the aging process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464372

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  61 in total

Review 1.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  Evaluation of serum carnitine levels for pediatric patients receiving carnitine-free and carnitine-supplemented parenteral nutrition.

Authors:  Brian Winther; Daniel Jackson; Cecilia Mulroy; Mark MacKay
Journal:  Hosp Pharm       Date:  2014-06

3.  Haplotype in the IBD5 region is associated with refractory Crohn's disease in Slovenian patients and modulates expression of the SLC22A5 gene.

Authors:  Katja Repnik; Uroš Potočnik
Journal:  J Gastroenterol       Date:  2011-06-22       Impact factor: 7.527

Review 4.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

5.  L-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation.

Authors:  G Fortin; K Yurchenko; C Collette; M Rubio; A-C Villani; A Bitton; M Sarfati; D Franchimont
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

Review 6.  Acetyl-L-carnitine in hepatic encephalopathy.

Authors:  Michele Malaguarnera
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

7.  Characterization of Pseudomonas aeruginosa growth on O-acylcarnitines and identification of a short-chain acylcarnitine hydrolase.

Authors:  Jamie A Meadows; Matthew J Wargo
Journal:  Appl Environ Microbiol       Date:  2013-03-22       Impact factor: 4.792

8.  Effects of L-carnitine on the formation of fatty acid ethyl esters in brain and peripheral organs after short-term ethanol administration in rat.

Authors:  V Calabrese; V Rizza
Journal:  Neurochem Res       Date:  1999-01       Impact factor: 3.996

9.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

Review 10.  Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.

Authors:  Carmen Mingorance; Rosalía Rodríguez-Rodríguez; María Luisa Justo; María Alvarez de Sotomayor; María Dolores Herrera
Journal:  Vasc Health Risk Manag       Date:  2011-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.